Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma (NCT02723006), a non-randomized phase 1 study. The primary outcome is Number of Dose Limiting Toxicities (DLTs) During the Dose-escalation Safety Lead-in Phase.

2. Clinical Question

The study’s stated purpose was to evaluate initial safety and tolerability, alongside initial antitumor activity, for the combinations in participants with advanced melanoma. Secondary outcomes named in the record include response rate, duration of response, progression-free survival, overall survival, and treatment-emergent and serious adverse events. The registry lists these outcomes but does not report numerical results for them in the record. The clinical question is therefore descriptive and early-stage: what safety events and activity measures were recorded during evaluation of these combinations, rather than whether one regimen outperformed a randomized comparator.

3. Trial Design

The registry describes NCT02723006 as an open-label, Phase 1b, multi-arm study. It was non-randomized, had no masking, and used a parallel model. Enrollment is listed as 22. The study began on 2016-06-22, and primary completion is listed as 2018-05-11. Its current status is terminated; the reason for termination is not reported in the registry record.

The three arms paired investigational treatments with standard-of-care immune checkpoint inhibitors. Arm 1 combined TAK-580 with nivolumab. TAK-580 was given orally once weekly, while nivolumab was given intravenously every 2 weeks. Arm 2 combined TAK-202 (plozalizumab) with nivolumab; the described TAK-202 schedule was 2 milligram intravenously in Week 1, 3, 5, 9, and every 4 weeks thereafter, with intravenous nivolumab every 2 weeks. Arm 3 combined vedolizumab, nivolumab, and ipilimumab. The registry describes intravenous schedules for each of those treatments. These arm-specific schedules are part of the treatment context and should not be treated as interchangeable exposure.

Because allocation was non-randomized and masking was absent, treatment assignment was not described as a concealed random process, and participants and investigators were not masked. The registry record does not report a randomized comparison, a common control arm, or a statistical adjustment strategy that would make between-arm differences causal estimates. The arms can be described separately, but their observed outcomes should not be read as a direct ranking of treatments.

The primary endpoint was a count of dose-limiting toxicities during the dose-escalation safety lead-in, with different stated observation windows for the two-drug and three-drug combinations. The record also lists five types of secondary outcome, including antitumor activity and adverse events. Although the study is described as having six outcome measures, the number of analyses recorded is 0. The registry record does not report a detailed analysis plan, a sample-size justification, or the reason the study was terminated.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Participants with advanced/metastatic melanoma were enrolled to receive:TAK-580+nivolumab,TAK-202+nivolumab,or vedolizumab+nivolumab+ipilumab. Study was terminated early after the dose escalation safety-lead in phase due to lack of enrollment(Arm 1), lack of clinical benefit(Arm 2), and after pre-specified stopping rule for diarrhea was met(Arm 3).

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: The safety analysis set included all participants who received at least 1 dose, even if incomplete, of study treatment (TAK-580, TAK-202, or vedolizumab).

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: The safety analysis set included all participants who received at least 1 dose, even if incomplete, of study treatment (TAK-580, TAK-202, or vedolizumab).

6. Primary Endpoint

The registry lists the primary outcome as Number of Dose Limiting Toxicities (DLTs) During the Dose-escalation Safety Lead-in Phase, measured over TAK-580 + Nivolumab and TAK-202 + Nivolumab: Baseline up to Week 9; Vedolizumab + Nivolumab + Ipilimumab: Baseline up to Week 7.

The primary endpoint is the number of dose-limiting toxicities during the dose-escalation safety lead-in. A dose-limiting toxicity is a safety event assessed under the named NCI CTCAE version 4.03 framework. In general, an endpoint of this kind is used in early-phase evaluation to describe whether treatment-related toxicities meet prespecified criteria during a defined exposure period. It is a count, not a measure of tumor response or survival.

The registry specifies the observation window as Baseline up to Week 9 for TAK-580 plus nivolumab and TAK-202 plus nivolumab, and Baseline up to Week 7 for vedolizumab plus nivolumab plus ipilimumab. Since those windows differ, endpoint counts would need to be interpreted in their arm-specific timing context. The safety analysis set is described as participants who received at least 1 dose, even if incomplete, of study treatment. The record does not provide the numerical dose-limiting toxicity results, the number of participants assessed for this endpoint by arm, or details of how missing endpoint assessments were handled.

The endpoint can indicate the observed burden of qualifying toxicities within the stated lead-in period, but by itself it does not establish comparative safety, later toxicity, or antitumor benefit. Those broader interpretations require outcomes and analyses beyond the primary endpoint count. Numerical primary results and their uncertainty are not reported in the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The statistical interpretation starts with the design. This was a parallel-arm, non-randomized study with no masking. In general, random allocation helps balance measured and unmeasured participant characteristics across treatment groups, while masking can reduce some forms of expectation-related influence on assessment. Neither feature is reported for this study. Accordingly, the arm-specific results are descriptive, and between-arm differences cannot automatically be attributed to the treatment combinations.

What does a count endpoint tell the reader?

The primary outcome is the number of dose-limiting toxicities during the dose-escalation safety lead-in. A count records how many qualifying events or participants were observed according to the endpoint definition; the registry labels its unit as DLTs and describes a safety analysis population. In general, counts are most interpretable alongside the number assessed, the observation period, and a clear definition of the counted event. The record names NCI CTCAE version 4.03 and gives arm-specific time windows, but does not report numerical primary results or endpoint-specific denominators.

The endpoint windows are not identical across all combinations: the two nivolumab combinations with TAK-580 or TAK-202 have a window through Week 9, while the vedolizumab combination has a window through Week 7. A count accumulated over one observation period is not directly equivalent to a count collected over a different period. General statistical practice may account for exposure time when the question requires it, but no such analysis is reported in the registry record.

Why does non-random allocation matter?

In a randomized comparison, the allocation process supports interpreting group differences under stated assumptions. Here, allocation is explicitly non-randomized. Participants in different arms may therefore have differed before treatment, and the record does not report how arm selection was made or whether statistical adjustment was planned. The three regimens also contain different combinations of drugs and schedules. This makes any unadjusted difference between arm-level counts difficult to separate from other differences. General explanatory caution is warranted: descriptive contrasts are not automatically causal effects.

The record lists no analyses. That means no formal hypothesis tests, model estimates, or precision measures are available to interpret for the outcomes summarized. A p-value, in general, describes how compatible data are with a specified statistical model and null hypothesis; it is not a measure of clinical importance. A confidence interval, in general, gives a range of values compatible with data under a particular method and assumptions. Neither is reported for the primary outcome in the registry record.

How should the adverse-event counts be read?

The safety entries give counts at risk and affected for serious events and for other events within each arm. These should be read as arm-specific descriptive totals, not as adjusted risks or comparisons. The registry also lists selected serious-event terms and percentages. A listed percentage does not by itself clarify how repeated events, multiple terms in one participant, or the event-specific denominator were handled. Those details are not reported in the registry record. It is also important to distinguish a number of participants affected from a number of event occurrences; the record presents participant counts for the arm-level summaries.

General statistical considerations include small denominators and sparse counts. When counts are sparse, estimates can be imprecise, and conventional large-sample approximations may be unreliable. Over-dispersion is a general issue when count variability exceeds the assumptions of a simple count model; it can make model-based uncertainty too narrow if ignored. No count model, dispersion assessment, or uncertainty calculation is reported, so these concepts explain possible analytical considerations rather than methods known to have been used in this study.

What does a planning illustration mean?

The stated planning illustration assumptions are a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation, with the effect to detect set as a stated fraction of the observed effect. For time-to-event outcomes, the illustration uses the total number of events under the Schoenfeld approach; for other outcomes, it expresses participants per arm. These are planning assumptions, not a description of the trial’s own design. Any sample-size illustration is not observed power and does not show the probability that this completed study detected an effect. The registry record does not report the study’s own sample-size justification. Since no numerical effect estimates for the outcomes are reported in the record, a reader should not infer additional planning values or trial power from these assumptions alone.

Finally, the registry lists six outcome measures and 0 analyses. The presence of outcome descriptions is not evidence that every endpoint was fully assessed or analyzed. The record does not report analysis populations by outcome, missing-data methods, handling of withdrawals, multiplicity procedures, or the statistical models used. Those omissions limit reconstruction of the analysis and assessment of the precision or robustness of any treatment-effect claim.

10. Multiplicity, Missing Data and Analysis Populations

The registry names a primary safety endpoint and several secondary outcomes, including response rate, duration of response, progression-free survival, overall survival, and treatment-emergent and serious adverse events. Considering multiple outcomes raises a general multiplicity issue: when many statistical tests are performed, the chance of at least one apparently unusual result can increase. Whether or how that issue was addressed depends on the prespecified analysis strategy. A multiplicity procedure or hierarchy is not reported in the registry record, and the record lists 0 analyses. No inferential results are reported for which multiplicity adjustment can be evaluated.

Missing-data handling is also not reported in the registry record. The primary endpoint description identifies the safety analysis set as participants who received at least 1 dose, even if incomplete, of study treatment. That definition does not specify how missing toxicity assessments, incomplete follow-up, treatment discontinuation, or absent secondary-outcome measurements were handled. The registry’s enrollment figure does not establish the endpoint-specific analysis denominator.

In general, missing outcomes can affect both the number of observations available and the interpretation of an estimate, particularly if missingness is related to health status, toxicity, or treatment discontinuation. Different assumptions about why data are missing may lead to different analyses. No imputation method, censoring rule, sensitivity analysis, or missingness assumption is reported in the registry record, so the impact cannot be quantified.

The record does not report an interim-analysis plan, stopping boundaries, or a statistical analysis plan. These details should not be inferred from the study’s terminated status. The reason for termination and whether any particular analysis decision followed from it are not reported in the registry record.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: nausea (100.0%), adrenal insufficiency (100.0%), rectal haemorrhage (11.1%), autoimmune colitis (8.3%), colitis (8.3%).

The registry reports arm-level counts for participants at risk and affected by serious adverse events and by other adverse events. For serious events, the entries are 1 at risk and 1 affected in Arm 1; 9 at risk and 2 affected in Arm 2; and 12 at risk and 7 affected in Arm 3. For other adverse events, the entries are 1 at risk and 1 affected in Arm 1; 9 at risk and 9 affected in Arm 2; and 12 at risk and 12 affected in Arm 3. These are descriptive registry counts, not adjusted estimates.

The record lists nausea and adrenal insufficiency at 100.0% among selected serious-event terms, along with rectal haemorrhage at 11.1%, autoimmune colitis at 8.3%, colitis at 8.3%, and diarrhoea at 8.3%. The event-term percentages are reported as listed; the registry record does not provide enough detail to establish the denominator or whether participants could contribute to more than one term. The terms should not be treated as mutually exclusive categories or as rates of all events without that information.

The deaths entries are 0 in Arm 1, 0 in Arm 2, and 2 in Arm 3. The record does not report cause or attribution for these deaths in the safety information described. Since the study was non-randomized and the arms used different combinations, the counts do not provide a controlled comparison of safety. They also do not, by themselves, describe event timing, duration, severity distribution, or causal relationship to treatment.

12. What the Result Does, and Does Not, Mean

The registry record establishes that NCT02723006 evaluated investigational treatment combinations with immune checkpoint inhibitors in participants with advanced melanoma. It describes a Phase 1b, open-label, non-randomized, parallel-arm design and gives the primary safety question: the number of dose-limiting toxicities during arm-specific lead-in windows. It also provides selected arm-level safety counts and event terms. These details describe the study’s scope and the outcomes recorded.

The record does not provide the numerical result for the primary endpoint. It also does not provide numerical results for the listed response, duration-of-response, progression-free-survival, or overall-survival outcomes. No analyses are listed. Without those results, the registry record cannot establish the observed size or precision of antitumor activity, nor can it support a statistical comparison among the combinations.

The adverse-event counts are useful as descriptive information about participants recorded as affected in each arm. They are not evidence that one combination is safer or more hazardous than another. Non-random allocation, different treatment regimens, and the absence of a reported adjusted comparison prevent a like-for-like interpretation. The listed event percentages also lack sufficient accompanying detail in this record to reconstruct their denominators and full event-level structure.

In general, early-phase safety studies can characterize observed tolerability during defined treatment and follow-up periods, while later or comparative questions require suitable design and complete outcome reporting. That general distinction does not fill gaps in this record. The registry does not report a rationale for termination, missing-data methods, a statistical analysis plan, or a sample-size justification. The study’s terminated status should not be interpreted as proof of a particular safety or efficacy conclusion.

The appropriate reading is therefore limited: the record documents the design, treatment schedules, primary safety endpoint definition, selected safety counts, and planned secondary outcome topics. It does not report enough statistical results to determine the efficacy or comparative safety of these combinations. Absence of a reported result is not evidence that an outcome was absent; it means the result is not reported in the registry record.

13. Why This Trial Matters Statistically

This study illustrates a common statistical challenge in early-phase combination research: several treatment regimens may be explored in parallel, while the primary aim is characterization of safety rather than a definitive efficacy comparison. The registry identifies three distinct combinations and an endpoint focused on dose-limiting toxicities during a dose-escalation safety lead-in. That framing matters because an early safety count answers a narrower question than a randomized clinical comparison.

The non-randomized allocation is central to interpretation. Even when arm-level numbers appear different, group composition and treatment schedules may also differ. Without randomization or a reported adjustment strategy, a difference cannot be attributed solely to the regimen. This is a design limitation, not a failure of a particular statistical test.

The record also demonstrates why endpoint definitions and denominators are essential. The lead-in assessment periods differ among combinations, while numerical primary results and endpoint-specific denominators are not reported. A count without its assessment context and analysis population is difficult to interpret precisely. Similarly, selected adverse-event terms require clear denominators and rules for participants who experience more than one term.

Finally, the registry lists several secondary outcomes but reports no analyses. A list of endpoints signals what was intended to be tracked, not what conclusions the data support. Transparent reporting of estimates, uncertainty, analysis populations, missing-data handling, and the statistical plan is needed to distinguish descriptive observations from evidence about comparative effects. This record is therefore useful for understanding the study’s design and reporting limits, while leaving its primary outcome result and broader treatment-effect questions unresolved.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main trial-specific limitation is that the numerical primary endpoint result is not reported in the registry record. The record defines the dose-limiting toxicity outcome, assessment windows, and safety analysis set, but does not give arm-specific counts for that endpoint or the number assessed. This prevents assessment of the observed primary safety result and its precision.

The study was non-randomized and had no masking. The registry does not report how participants entered each arm, whether baseline characteristics differed, or whether an adjustment strategy was used. Because the regimens also differ in their component drugs and schedules, descriptive differences across arms are not controlled comparisons. The study’s enrollment is listed as 22, but the record does not give an endpoint-by-endpoint accounting of participants analyzed.

Further limitations are reporting gaps. The registry lists secondary outcomes but gives no numerical findings for them and lists 0 analyses. It does not report confidence intervals, p-values, analysis models, a statistical analysis plan, multiplicity procedures, or missing-data methods. The reason for termination, interim analyses, and a sample-size justification are also not reported in the registry record. These omissions prevent evaluation of prespecification, precision, and the potential influence of incomplete outcome data.

Safety information is descriptive and includes selected event terms. The record does not fully specify event-term denominators, event timing, attribution, or how multiple terms in one participant were handled. The deaths entries are reported by arm, but causes and attribution are not reported in the safety information. These limitations do not negate the recorded counts; they restrict what can be inferred from them.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma — NCT02723006.
• Registry record last updated 2024-03-05; status last verified 2024-02.
• Results first posted 2021-04-01.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT02723006 is a terminated, open-label, Phase 1b, non-randomized, parallel-arm study in advanced melanoma. Enrollment is listed as 22. The three regimens paired TAK-580 with nivolumab, TAK-202 (plozalizumab) with nivolumab, or vedolizumab with nivolumab and ipilimumab.

The primary outcome was the number of dose-limiting toxicities during the dose-escalation safety lead-in, assessed under NCI CTCAE version 4.03. The registry gives different lead-in windows by regimen but does not report numerical primary endpoint results. It names response, duration of response, progression-free survival, overall survival, and adverse events as secondary outcomes. No analyses are listed.

Arm-specific serious and other adverse-event counts and selected serious-event terms are reported. Because allocation was non-randomized and the arms used different combinations, these figures are descriptive rather than a controlled comparison. The reason for termination, sample-size justification, missing-data methods, and statistical analysis plan are not reported in the registry record.